Julie Segal Why Biotech Struggles to Finish What It Starts As more drugs stall between early data and approval, Geoffrey Meyerson’s Banyan BioInnovations is testing a new investment approach for biotech’s most expensive and underfunded phase. Julie Segal May 5, 2026